Tellus Therapeutics develops novel small molecules derived from human maternal breast milk.
Tellus Therapeutics has raised $16.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2023.
Tellus Therapeutics's investors include MassChallenge, Xontogeny, North Carolina Biotechnology Center, One North Carolina Small Business Program.
Tellus Therapeutics is headquartered in Hillsborough, United States.
Tellus Therapeutics develops novel small molecules derived from human maternal breast milk.
Tellus Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tellus Therapeutics — Funding & Investors." VCBacked, February 21, 2023, https://www.vcbacked.co/company/tellus-therapeutics. Accessed November 12, 2026.
VCBacked. (2023). Tellus Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/tellus-therapeutics
{{cite web |title=Tellus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tellus-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Tellus Therapeutics? Request a listing update